🏛️ Verified NIH Record • Updated 2026-07-29

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) (NCT04784715)

Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic setting.

Who can join: Review the eligibility criteria below.

Location: Research Site — Tucson, Arizona

Age range: 18 Years to 130 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (283 Sites)

Showing the first 25 of 283 sites.

  • Research Site — Tucson, Arizona
  • Research Site — Springdale, Arkansas
  • Research Site — Glendale, California
  • Research Site — Glendale, California
  • Research Site — Longmont, Colorado
  • Research Site — Miami, Florida
  • Research Site — Palm Bay, Florida
  • Research Site — Plantation, Florida
  • Research Site — Atlanta, Georgia
  • Research Site — Louisville, Kentucky
  • Research Site — Silver Spring, Maryland
  • Research Site — Boston, Massachusetts
  • Research Site — Detroit, Michigan
  • Research Site — Jackson, Mississippi
  • Research Site — Las Vegas, Nevada
  • Research Site — Summit, New Jersey
  • Research Site — New York, New York
  • Research Site — Shirley, New York
  • Research Site — York, Pennsylvania
  • Research Site — Germantown, Tennessee
  • Research Site — Dallas, Texas
  • Research Site — Dallas, Texas
  • Research Site — Denton, Texas
  • Research Site — Houston, Texas
  • Research Site — San Antonio, Texas

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Breast Cancer; HER2-positive; Metastatic clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗